"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Descriptor ID |
D017024
|
MeSH Number(s) |
E02.186.170 E02.319.170
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 20 | 21 |
1995 | 1 | 17 | 18 |
1996 | 1 | 23 | 24 |
1997 | 2 | 21 | 23 |
1998 | 0 | 34 | 34 |
1999 | 0 | 26 | 26 |
2000 | 2 | 24 | 26 |
2001 | 1 | 16 | 17 |
2002 | 2 | 24 | 26 |
2003 | 2 | 59 | 61 |
2004 | 4 | 61 | 65 |
2005 | 6 | 63 | 69 |
2006 | 7 | 82 | 89 |
2007 | 9 | 57 | 66 |
2008 | 3 | 66 | 69 |
2009 | 3 | 65 | 68 |
2010 | 2 | 79 | 81 |
2011 | 4 | 70 | 74 |
2012 | 3 | 61 | 64 |
2013 | 2 | 54 | 56 |
2014 | 2 | 58 | 60 |
2015 | 12 | 70 | 82 |
2016 | 6 | 63 | 69 |
2017 | 6 | 64 | 70 |
2018 | 3 | 65 | 68 |
2019 | 8 | 55 | 63 |
2020 | 7 | 52 | 59 |
2021 | 2 | 52 | 54 |
2022 | 0 | 26 | 26 |
2023 | 0 | 24 | 24 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
The effects of oxaliplatin-based?adjuvant?chemotherapy?in?high-risk?stage?II?colon?cancer with mismatch repair-deficient: a retrospective study. BMC Cancer. 2024 Feb 02; 24(1):164.
-
ASO Visual Abstract: Trends in Locoregional Therapy in Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer by Frailty and Life Expectancy. Ann Surg Oncol. 2024 02; 31(2):1021-1022.
-
HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category. Hum Pathol. 2023 Dec; 142:34-41.
-
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2023 Dec; 24(12):1359-1374.
-
Great Debate: Chemoradiation Should be Added to Chemotherapy as a Neoadjuvant Treatment Strategy for Resectable Gastric Adenocarcinoma. Ann Surg Oncol. 2024 Jan; 31(1):405-412.
-
National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. Breast Cancer Res Treat. 2024 Jan; 203(2):317-328.
-
Progress and emerging strategies to preserve function in the treatment of sinonasal cancer. Head Neck. 2023 11; 45(11):2955-2966.
-
Adjuvant therapy in high-risk, node-negative melanoma. Clin Adv Hematol Oncol. 2023 08; 21(8):445-448.
-
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. J Clin Oncol. 2023 10 01; 41(28):4535-4547.
-
Unraveling the Benefit of Adjuvant Chemotherapy in Early-Stage Combined Small Cell Lung Cancer. Ann Thorac Surg. 2023 12; 116(6):1149.